Global Adult Vaccines Market Size, Share, Growth Analysis Report - Forecast 2034

Global Adult Vaccines Market: Industry Perspective

The global adult vaccines market size was worth around USD 33.30 Billion in 2024 and is predicted to grow to around USD 63.69 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 6.7% between 2025 and 2034. The report analyzes the global adult vaccines market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the adult vaccines industry.

Request Free Sample

Global Adult Vaccines Market: Overview

Vaccination is of huge significance for public health as it helps in improving the body's immunity. Apart from this, vaccination is the main mode to prevent ailments in infants as well as children and adults to avoid mortality and illness. Furthermore, the eradication of deadly diseases can be prevented successfully through vaccination. Vaccination is an important part of public health programs globally.

According to NCBI, every year vaccine-preventable ailments cause the death of many adults in countries like the U.S. Moreover, as per CDC, adults need a vaccine for influenza each year as the vaccine is this flu vaccine is necessary for persons suffering from chronic illness, elder persons, and pregnant women. As per CDC recommendations, each adult must be inoculated with the Tdap (Tetanus, Diphtheria, and Pertussis) vaccine once for getting protection against whooping cough if the adult did not get inoculated. Furthermore, Td (tetanus, diphtheria) booster inoculation is provided every 10 years for adults. Additionally, pregnant ladies are recommended to get vaccinated through the Tdap vaccine during a time of pregnancy each time during 27 to 36 weeks of pregnancy.

Furthermore, the CDC also recommends the HPV vaccine for adults aged between 19 to 26 years which helps in offering them protection against various kinds of human papillomaviruses causing anal & cervical cancers as well as against genital warts if not vaccinated in early teens. Moreover, adults more than 50 years of age are recommended shingles vaccination, pneumococcal polysaccharide vaccine that offers protection against meningitis & other blood infections, and pneumococcal conjugate vaccine offering protection against pneumonia and pneumococcal ailment. As per NCBI, adult vaccination is also recommended for zoster, measles, hepatitis A, rubella, mumps, hepatitis B, and Haemophilus influenza B.

Global Adult Vaccines Market: Growth Factors

Rise in the spread of infectious diseases will accentuate the global market growth by 2030

The growing occurrence of contagious ailments in adults along with a rise in the initiatives taken by the government supporting vaccine development for adults will boost the global adult vaccines market trends. Furthermore, rising associations of the government with pharmaceutical & biopharmaceutical firms for developing novel vaccines will favorably leverage the growth of the market in the years ahead. Furthermore, a breakthrough in the biomedical domain is predicted to pave the way for the growth of the global market in the years ahead. In addition to this, the rise in new product launches along with collaborations between industry players and the government will promulgate the growth of the market across the globe in the ensuing years.

Moreover, approval of vaccines by government authorities in countries such as the U.S. will also promote the growth of the adult vaccines market across the globe. For instance, in May 2023, GSK plc declared that the U.S. FDA approved Arexvy, the first respiratory syncytial virus (RSV) vaccine for the adult population aged 60 and more, for preventing lower respiratory tract ailment occurring due to respiratory syncytial virus in people aged 60 years and above.

Adult Vaccines Market: Restraints

Low awareness about the benefits of adult vaccination in developing countries can put brakes on the global industry expansion

Lack of awareness about adult vaccines in emerging economies and remote areas as well as rural areas can prove detrimental to the expansion of the global adult vaccines industry. A rise in the up-front costs of the products can further retard the expansion of the global industry in the upcoming years. The absence of proficient reminder systems and implementation barriers such as the need for special refrigerators for storing adult vaccines can retard the global industry expansion.

Adult Vaccines Market: Opportunities

A high focus on increasing awareness about vaccination among adults can open new vistas of growth for the market across the globe

A large number of emerging economies are carrying out national vaccination programs to create awareness about the benefits of vaccines among the people. This, in turn, will open new growth opportunities for the global adult vaccines market. Growing government focus on preventing chronic diseases and avoiding pandemics can further increase the popularity of adult vaccination programs, thereby helping the market across the globe explore new horizons of growth in the years to come.

Adult Vaccines Market: Challenges

Lack of favorable reimbursement government policies can halt the growth of the industry globally over the forecast period

Infrastructural constraints and poor compensation related to adult vaccines witnessed in emerging economies can pose a huge challenge to the expansion of the adult vaccines industry across the globe. Apart from this, hesitancy to get vaccinated among a large adult population due to the perception that there is no need to get vaccinated to prevent the occurrence of diseases can prove to be a huge impediment to the global industry surge.

Key Insights

• As per the analysis shared by our research analyst, the global adult vaccines market is estimated to grow annually at a CAGR of around 6.7% over the forecast period (2025-2034).
• Regarding revenue, the global adult vaccines market size was valued at around USD 33.30 Billion in 2024 and is projected to reach USD 63.69 Billion by 2034.
• The adult vaccines market is projected to grow at a significant rate due to Growing awareness of preventive healthcare and increasing elderly population drive demand. Government immunization programs and new vaccine developments support growth.
• Based on Vaccine Type, the Influenza segment is expected to lead the global market.
• On the basis of Technology, the Inactivated & Subunit segment is growing at a high rate and will continue to dominate the global market.
• Based on the Application, the Preventive segment is projected to swipe the largest market share.
• By Distribution Channel, the Hospitals segment is expected to dominate the global market.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Global Adult Vaccines Market: Report Scope

Global Adult Vaccines Market: Segmentation Analysis

The global adult vaccines market is segmented based on Vaccine Type, Technology, Application, Distribution Channel, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2025 to 2034.

Based on Vaccine Type, the global adult vaccines market is divided into Influenza, Tetanus, Diphtheria & Pertussis, HPV, Hepatitis, Pneumococcal, COVID-19, Others.

On the basis of Technology, the global adult vaccines market is bifurcated into Inactivated & Subunit, Live Attenuated, Toxoid, Conjugate, Recombinant, mRNA.

By Application, the global adult vaccines market is split into Preventive, Therapeutic.

In terms of Distribution Channel, the global adult vaccines market is categorized into Hospitals, Clinics, Pharmacies, Government Supply Programs.

The Regional, this segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America,and the Middle East and Africa.

Global Adult Vaccines Market: Regional Insights

North America leads the adult vaccines market, accounting for around 40 % of global revenue in the mid-2020s—driven by strong government support (CDC, FDA), high preventive healthcare awareness, and a robust industrial base—while Europe also demonstrates solid growth under proactive immunization policies. The Asia–Pacific region is the fastest-growing, fueled by large populations in India, China, and Japan, rising incomes, government-driven programs like India’s Mission Indradhanush, improving healthcare access, and expanding local vaccine production capacity. Latin America and the Middle East & Africa show moderate but steady expansion, with vaccine imports supplemented by growing private sector participation and public initiatives supported by organizations like PAHO. Across all regions, the global adult vaccines market is projected to grow at a compound annual rate of approximately 6–9 % from 2025 to 2034, reflecting rising adult disease prevalence, technological advances (e.g., mRNA, recombinant platforms), and enhanced immunization programs.

Global Adult Vaccines Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the adult vaccines market on a global and regional basis.

The global adult vaccines market is dominated by players like:

• Solvay Pharmaceuticals
• Moderna
• BioCSL (Seqirus)
• Aventis Pasteur
• Sanofi Pasteur
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline Plc
• Novartis AG
• Johnson & Johnson
• BioNTech
• Bharat Biotech International Limited
• Zhifei
• Wyeth Vaccines
• AstraZeneca Plc
• Medimmune
• Sinovac
• Baxter International Healthcare Company
• Chiron Vaccines
• Serum Institute of India.

Global Adult Vaccines Market: Segmentation Analysis

The global adult vaccines market is segmented as follows;

By Vaccine Type

• Influenza
• Tetanus
• Diphtheria & Pertussis
• HPV
• Hepatitis
• Pneumococcal
• COVID-19
• Others

By Technology

• Inactivated & Subunit
• Live Attenuated
• Toxoid
• Conjugate
• Recombinant
• mRNA

By Application

• Preventive
• Therapeutic

By Distribution Channel

• Hospitals
• Clinics
• Pharmacies
• Government Supply Programs

Global Adult Vaccines Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America